Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|20|20|2537-2551

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.20, Iss.20, 2013-07, pp. : 2537-2551

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Proteasome Inhibitors in Cancer Therapy

By  

Current Drug Targets, Vol. 10, Iss. 10, 2009-10 ,pp. : 968-981

Bentham Science Publishers

Access to resources Recommend Favorite

A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 14, 2007-07 ,pp. : 1408-1422

Bentham Science Publishers

Access to resources Recommend Favorite

The potential of proteasome inhibitors in cancer therapy

By Sterz Jan   Metzler Ivana von   Hahne Jens-Claus   Lamottke Britta   Rademacher Jessica   Heider Ulrike   Terpos Evangelos   Sezer Orhan  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 879-895

Informa Healthcare

Access to resources Recommend Favorite

Akt inhibitors in clinical development for the treatment of cancer

By Pal Sumanta Kumar   Reckamp Karen   Yu Hua   Figlin Robert A  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1355-1366

Informa Healthcare

Access to resources Recommend Favorite

CDK inhibitors in clinical development for the treatment of cancer

By Fischer Peter M   Gianella-Borradori Athos  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 6, 2003-06 ,pp. : 955-970

Informa Healthcare

Access to resources Recommend Favorite